AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year - July 20, 2026
About this episode
The episode discusses the significant milestones in AI drug discovery, focusing on Isomorphic Labs and Insilico Medicine's advancements in clinical trials.
AI Designed Drugs Face Their Reckoning: Isomorphic Labs, Insilico's Phase 3, and Medicine's Make or Break Year Two milestones just turned AI drug discovery from promise into a real world test. Isomorphic Labs, the Google DeepMind spinoff built on the AlphaFold lineage, is moving its first AI designed molecules into human oncology trials, while Insilico Medicine has pushed rentosertib, an AI discovered treatment for the lung disease idiopathic pulmonary fibrosis, into a pivotal Phase 3 study...
More episodes of DX Today | No-Hype Podcast & News About AI & DX
- The Broken Apprenticeship: AI, the 35% Entry-Level Collapse, and the Redesign of Law, Finance, and Consulting - July 21, 2026
- DX Today AI Daily Brief - Tuesday, July 21, 2026
- DX Today AI Daily Brief - Monday, July 20, 2026
- Inkling Arrives: Mira Murati's 975 Billion Parameter Open Weight Bet Against One Size Fits All AI - July 19, 2026
- DX Today AI Daily Brief - Sunday, July 19, 2026
- The Shanghai Counterweight: China's 29 Nation WAICO Alliance and the Two Futures of Global AI Governance - July 18, 2026
Explore listener stats, chart rankings, contacts and more on the DX Today | No-Hype Podcast & News About AI & DX podcast page.